Q4 2019 Novocure Ltd Earnings Call
Novocure and Zai Lab announced that China NMPA approved Optune® for the treatment of newly diagnosed and recurrent glioblastoma.
Q1 2020 Novocure Ltd Earnings Call
NovoCure (NVCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
In 2002 Asaf Danziger was appointed CEO of NovoCure Limited (NASDAQ:NVCR). This analysis aims first to contrast CEO...
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Novocure stock sagged Thursday after the cancer treatment specialist delayed the results of several key studies and reported first-quarter measures that lagged some estimates.
Preclinical data on Tumor Treating Fields in combination with anti-PD-1 therapy were published in the journal Cancer Immunology, Immunotherapy.
Novocure reported financial results for the first quarter of 2020 and provided a company update.
On behalf of the entire NovoCure team, we would like to begin by wishing you well as we collectively face the challenges of the COVID-19 pandemic. Pritesh Shah, our Chief Commercial Officer; and Ely Benaim, our Chief Medical Officer, are also on the call and available for Q&A.
NovoCure Limited (NASDAQ:NVCR), which is in the medical equipment business, and is based in Jersey, received a lot of...
NovoCure (NVCR) delivered earnings and revenue surprises of -20.00% and -2.19%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Novocure announced that EF-19 post-approval registry trial data will be presented at the AACR 2020 Virtual Annual Meeting I.
Novocure announced today that Optune Lua is the brand name for the NovoTTF-100L System in malignant pleural mesothelioma (MPM).
NovoCure (NVCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NovoCure (NVCR) delivered earnings and revenue surprises of 300.00% and 0.11%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Novocure today provided an update on its response to the COVID-19 pandemic.
We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was trading at the 3150 level. We also told you to short the market and buy […]
The German Federal Joint Committee issued a final coverage directive, establishing national reimbursement of Optune in newly diagnosed GBM in Germany.
Medical Services Outlook Bright Amid Coronavirus Crisis